This week's Morbidity and Mortality Weekly Report from the Centers for Disease Control and Prevention (CDC) highlights the reduction of bloodstream infections in an outpatient hemodialysis center participating in CDC's Dialysis Bloodstream Infection Prevention Collaborative.
One New Jersey facility participating in the collaborative reduced access-related bloodstream infections and only had one bloodstream infection in the last 12 months. Bloodstream infections are a serious concern for patients undergoing hemodialysis, but are preventable with the implementation of recommended infection prevention strategies.
The CDC collaborative is a partnership of freestanding and hospital-based outpatient dialysis facilities that aims to prevent bloodstream infections in dialysis patients. For more information, visit http://www.cdc.gov/dialysis/collaborative/index.html.
To read about New Jersey's success: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6110a2.htm?s_cid=mm6110a2_e%0d%0a
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.